A Phase 1, First-In-Human Study of Escalating Doses of Oral TVB-2640 in Patients With Solid Tumors
Status:
Completed
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
This first in human phase 1 study of TVB-2640 is being conducted in patients with advanced
stage solid malignant tumors. This research is being done to find out how safe and useful
TVB-2640 is for patients who have received previous cancer therapy, and for whom no therapy
exists that would be curative or might provide significant benefit. TVB-2640 belongs to a
class of drugs called fatty acid synthase inhibitors (FASN inhibitors). This means that they
interfere with the body's (and the tumor's) ability to use a substance called fatty acid
synthase (FASN). Research has shown that some tumors appear to need FASN to keep growing.